SCHEMBL8515539

SCHEMBL8515539

C#CCOCC(C)=CCc1cc(Br)ccc1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.36
PTGS2 P35354 1/20 0.36
BACE1 P56817 1/20 0.36
HTT P42858 3/20 0.36
HPGD P15428 3/20 0.35
ALDH1A1 P00352 4/20 0.35
TSHR P16473 1/20 0.33
GFER P55789 1/20 0.33
AKR1B10 O60218 1/20 0.33
AKR1B1 P15121 1/20 0.33
AKR1C3 P42330 1/20 0.33
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
PKM P14618 1/20 0.32
HIF1A Q16665 1/20 0.32
PTPN1 P18031 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8515538 1.00 PTGS1 (0.36) PTGS1PTGS2BACE1HTTHPGD
SCHEMBL8513968 0.81 HPGD (0.39) HTTHPGDALDH1A1TSHRKDM4E
SCHEMBL9932317 0.81 HPGD (0.39) HTTHPGDALDH1A1TSHRKDM4E
SCHEMBL14139155 0.74 HTT (0.60) PTGS1PTGS2HTTHPGDALDH1A1
SCHEMBL20468251 0.64 PYCR1 (0.54) HTTHPGDALDH1A1TSHRGFER
SCHEMBL789209 0.64 ERN1 (0.52) HTTHPGDALDH1A1TSHRGFER
SCHEMBL547469 0.64 GABRA1 (0.66) HTTHPGDALDH1A1TSHRGFER
Formaldehyde SCHEMBL28004393 0.62 GABRA1 (0.61) HTTHPGDALDH1A1TSHRGFER
SCHEMBL15299051 0.61 ALDH1A1 (0.51) HTTHPGDALDH1A1TSHRGFER
SCHEMBL82273 0.61 ALDH1A1 (0.54) BACE1HTTHPGDALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES GENENTECH, INC. 2012-06-21 US disclosed
WO-2012071458-A1 HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157448-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES BACE1, PSEN1, PSEN2 PTGS1 974/4885PTGS2 1598/4885BACE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.